147 related articles for article (PubMed ID: 32787747)
1. Autophagic Vacuole Secretion Triggered by Chidamide Participates in TRAIL Apoptosis Effect in Breast Cancer Cells.
Zhou W; Han H; Xu J; Sun T; Feng X
Curr Pharm Des; 2021; 27(20):2366-2380. PubMed ID: 32787747
[TBL] [Abstract][Full Text] [Related]
2. Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.
Di X; Zhang G; Zhang Y; Takeda K; Rivera Rosado LA; Zhang B
Oncotarget; 2013 Sep; 4(9):1349-64. PubMed ID: 23988408
[TBL] [Abstract][Full Text] [Related]
3. Chidamide enhances cytotoxicity of doxorubicin by promoting autophagy and apoptosis in breast cancer.
Li J
BMC Cancer; 2023 Apr; 23(1):353. PubMed ID: 37069549
[TBL] [Abstract][Full Text] [Related]
4. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
5. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Zhao B; He T
Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Zhou J; Zhang C; Sui X; Cao S; Tang F; Sun S; Wang S; Chen B
Invest New Drugs; 2018 Aug; 36(4):571-580. PubMed ID: 29504068
[TBL] [Abstract][Full Text] [Related]
7. Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Kong YL; Pan BH; Liang JH; Zhu HY; Wang L; Xia Y; Wu JZ; Fan L; Li JY; Xu W
Aging (Albany NY); 2020 Aug; 12(16):16083-16098. PubMed ID: 32855355
[TBL] [Abstract][Full Text] [Related]
8. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
10. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
11. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
13. [Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response].
Xu L; Tang HL; Gong X; Xin XL; Dong Y; Gao GX; Shu MM; Chen XQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):450-4. PubMed ID: 25948203
[TBL] [Abstract][Full Text] [Related]
14. Ganoderma immunomodulatory protein and chidamide down-regulate integrin-related signaling pathway result in migration inhibition and apoptosis induction.
Lu CT; Leong PY; Hou TY; Huang SJ; Hsiao YP; Ko JL
Phytomedicine; 2018 Dec; 51():39-47. PubMed ID: 30466626
[TBL] [Abstract][Full Text] [Related]
15. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model.
Wang SC; Yu CY; Wu YC; Chang YC; Chen SL; Sung WW
Cancer Lett; 2022 Apr; 530():8-15. PubMed ID: 35033588
[TBL] [Abstract][Full Text] [Related]
16. In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Xie Y; Tang P; Xing X; Zhao Y; Cao S; Liu S; Lu X; Zhong L
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Nov; 241():118669. PubMed ID: 32653824
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Profiling Analysis Identifies LCP1 as a Contributor for Chidamide Resistance in Gastric Cancer.
Bao W; Zhu Z; Gao Y; Chen J
Pharm Res; 2022 May; 39(5):867-876. PubMed ID: 35578065
[TBL] [Abstract][Full Text] [Related]
18. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
19. The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF‑κB pathway in multiple myeloma cells.
Liu Z; Jing Q; Wang Y; Li Y; Mi F; Xiang C; Fu R
Int J Mol Med; 2019 Jan; 43(1):285-293. PubMed ID: 30387821
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
